Navigation Links
Anti-cancer drug may treat muscular dystrophy

Recent studies on mice reveal that a drug, being tested as an anticancer agent to treat breast cancer, supports recovery from muscular dystrophy//, a disease that has no cure.

Duchene muscular dystrophy is a disease characterized by progressive weakness and degeneration of the muscles that control movement. According to earlier studies, the functional decline of "dystrophic" muscles can be slowed down by agents that enhance muscle fiber size.

The recent study conducted by Dr. P. L. Puri, from The Burnham Institute in La Jolla, California, and colleagues is published on line yesterday in the journal Nature Medicine. According to this study, the anticancer drug trichostatin A or TSA increases muscles fiber size in two mouse models of muscular dystrophy. Mice with this disability, when given TSA for 3 months, were able to run on treadmills and swim as long as healthy mice. According to the researchers, the drug caused no obvious side effects or signs of toxicity. TSA belongs to a class of drugs called deacetylase inhibitors.

The dystrophic muscles became resistant to contraction-related degeneration when treated with trichostatin A and this is linked with functional and morphological recovery. "We have identified a new rationale for treating muscular dystrophy, aimed at correcting the devastating effects of a single flawed gene," Dr Lorenzo Puri said in a statement. "In the window of time that we have analysed these mice, they seem to perform like normal mice. All the decreases in muscle performance were restored by the treatment. "This is a significant advance over the use of steroid -- currently the only treatment available -- which offers palliative relief, often with severe side effects," he said.

Ms Sharon Hesterlee, a vice-president of the association, which helped finance the research, said "I am hesitant to call the finding a breakthrough, because that could raise expectations unfairly, but it's certainly an i mportant finding."

Puri said, "Extensive investigation is now required to determine if these animal findings also apply to humans with muscular dystrophy. It is difficult to predict how long it will take before these studies will be translated into therapies for human patients," he added. "The next step is to test TSA on larger animals, such as golden retrievers, which contract a form of muscular dystrophy more similar to that in humans, " Dr Puri said.

One in every 3,500 male births is affected by this inherited disease. According to the Muscular Dystrophy Association, 40,000-60,000 people in the US have some form of the inherited disease.

Related medicine news :

1. An Anti-cancer Smart Bomb delivered using a Nanocell
2. Gene Study Offers Hope of Potent Anti-cancer Drugs
3. Indian Court Refers Novartis Plea for Patent on Anti-cancer Drug to a Separate Board
4. Thyroid hormone treatment hastens recovery after cardiac surgery
5. Feeding channel created by malaria parasite - a new target for malaria treatments
6. New drug to treat Heart Attack and damaged tissue
7. Now umbilical cord helps in stroke treatment.
8. Now AIDS treatment comes dirt-cheap
9. Breast cancer treatment to be determined by gene test
10. Hemopurifier may revolutionise AIDS treatment
11. New drug helps boost cancer treatment
Post Your Comments:

(Date:11/25/2015)... ... November 25, 2015 , ... The holiday ... dish and pleasing the palates of attendees is of the utmost importance. Whether ... a seasonal get-together, give these recipes a try this holiday season. , Turkey ...
(Date:11/25/2015)... Nairobi (PRWEB) , ... November 26, 2015 , ... ... African Union Commission (AUC), European Union (EU), ANDI Pan African Centres of Excellence, ... Nations Office in Nairobi (UNON) for the opening of the 5th African Network ...
(Date:11/25/2015)... ... 25, 2015 , ... Dental professionals who would like to become more proficient ... attend Dr. Mark Iacobelli’s Advanced Implant Mentoring (AIM) CE course. Courses will be held ... the co-founders of Advanced Implant Mentoring (AIM), Dr. Iacobelli and Dr. D’Orazio are proud ...
(Date:11/25/2015)... ... 2015 , ... Smiles by Stevens is pleased to announce the ... While many patients are aware of the benefits of Botox® in the treatment of ... suffering with discomfort, soreness, and pain as a result of Jaw Tension, TMJ (temporo-mandibular ...
(Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, I saw a ... “I thought there had to be a convenient and comfortable way to protect them ... enables disabled individuals to safely travel during cold or inclement weather. In doing so, ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... -- ) has announced the ... Viscosity Drugs" report to their offering. ... of the "Self Administration of High Viscosity ... Research and Markets ( ) has ... of High Viscosity Drugs" report to their ...
(Date:11/26/2015)... November 26, 2015 ... addition of the  "2016 Future Horizons ... Cell Surface Marker Testing Market: Supplier ... to their offering.  --> ... of the  "2016 Future Horizons and ...
(Date:11/25/2015)... , Nov. 25, 2015  Amgen (NASDAQ: AMGN ... Application (BLA) with the United States ... 501, a biosimilar candidate to Humira ® (adalimumab). ... application submitted to the FDA and represents Amgen,s first ... Sean E. Harper , M.D., executive vice president of ...
Breaking Medicine Technology: